Cytoplasmic expression of antibodies, antibody fragments and antibody fragment fusion proteins in E. coli

US6602688B1 · kind B1 · utility

Assignee

• Aventis Pharma Deutschland GmbH · DE

Inventors

• Martin Opper · Marburg, DE
• Klaus Bosslet · Marburg, DE
• Joerg Czech · Marburg, DE

Key dates

• Filing date: Mar 22, 1999
• Grant date: Aug 5, 2003
• Expiry date: Mar 22, 2019

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y10S435/849
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to the cytoplasmic expression of antibodies, antibody fragments and antibody fragment fusion molecules in E. coli. In particular, antibody fragment fusion molecules having an antibody moiety which is directed against tumors and an enzyme moiety which cleaves a nontoxic prodrug to give the toxic drug can be advantageously prepared in this way while retaining their respective functional properties.